WBA - Walgreens Boots Alliance, Inc.
Pre-Market:
| Previous Close | 31.93 |
| Open | 31.93 |
| Bid | 31.68 x 2200 |
| Ask | 32.00 x 800 |
| Day's Range | 31.56 - 31.97 |
| 52 Week Range | 29.48 - 42.74 |
| Volume | |
| Avg. Volume | 7,186,465 |
| Market Cap | 27.48B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings Date | Jun 27, 2023 |
| Forward Dividend & Yield | 1.92 (6.09%) |
| Ex-Dividend Date | May 18, 2023 |
| 1y Target Est | 40.00 |
Motley Fool2 Dow Stocks That Are Screaming Buys in June and 1 to Avoid Like the Plague
The ageless Dow Jones Industrial Average has two phenomenal deals hiding in plain sight, as well as one company that's priced for perfection.
Business WireWalgreens Boots Alliance Sells Remaining Shares of Option Care Health for Approximately $330 Million of Proceeds
DEERFIELD, Ill., June 09, 2023--WBA sells remaining shares of Option Care Health for approximately $330 million of proceeds.
Motley FoolThese 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Shares of e-commerce company Etsy (NASDAQ: ETSY) have dropped more than 20% so far this year. First, Etsy has managed to keep the gains it made over the past few years. The company's total gross merchandise sales (GMS) soared more than 200% in the first quarter compared to the same quarter four years ago.
ZacksWalgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
Walgreens Boots Alliance (WBA) closed the most recent trading day at $31.93, moving +1.27% from the previous trading session.
Motley FoolIs It Time to Buy the Dow Jones' 3 Worst-Performing May Stocks?
These Dow Jones laggards logged double-digit declines in May. Are their fortunes turning, or is more misery on the way?
Motley FoolBetter Buy: CVS vs. Walgreens Stock
The competition in retail pharmacy is intense. Neither of these stocks has been a winner for investors over the last 12 months. Here's how two Motley Fool contributors think CVS and Walgreens stack up against each other.
ZacksWalgreens (WBA) Upgraded to Buy: Here's What You Should Know
Walgreens (WBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Business WireWalgreens Boots Alliance Schedules Fiscal 2023 Third Quarter Earnings Announcement for June 27, 2023
DEERFIELD, Ill., June 05, 2023--WBA will release its fiscal 2023 third quarter results at 7 a.m. ET on Tuesday, June 27, 2023.
ZacksWalgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
ZacksWalgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
Walgreens Boots Alliance (WBA) closed the most recent trading day at $30.32, moving -0.16% from the previous trading session.
Motley Fool3 Numbers That Could Make You Think Twice About Walgreens' Dividend
Investors may want to resist the temptation to load up on a dividend that could end up being too good to be true.
Motley Fool3 Top Stocks That Just Went on Sale
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
Motley FoolWalgreens Just Got Another Piece of Bad News -- Should You Sell Its Stock?
The problem this time around is another instance of one of the company's bugbears over the last few years: legal settlements pertaining to its filling of opioid drug prescriptions. The latest piece of bad news is that Walgreens agreed on May 17 to a $230 million settlement with the city of San Francisco, which was suing it for lack of sufficient due diligence when it filled prescriptions for opioid medications.
ZacksWalgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $30, marking a +0.1% move from the previous day.
The GuardianBoots boss more than doubles pay to £3.8m as chain triples profits
Chemist made a profit of £137m in year to 31 August, helped by closure of 44 underperforming stores
ReutersPharmacy chain Walgreens Boots Alliance to cut corporate jobs by 10%
Walgreens Boots Alliance Inc said on Friday it would slash its corporate staff by about 10%, as it streamlines operations and focuses on consumer-facing healthcare businesses.
Motley FoolWall Street Expects This Stock to Skyrocket 30%. Is That Realistic?
Shares of the pharmaceutical services leader have fallen close to 17% so far this year while the S&P 500 has risen nearly 8%. Walgreens could be poised to rebound, though. Wall Street expects the stock to skyrocket by 30%.
Motley Fool3 Iconic Dow Stocks That Can Safely Double Your Money by 2028
The Dow Jones Industrial Average is composed of 30 time-tested, multinational businesses. Three of them are capable of delivering triple-digit total returns over the next five years.
Business WireWalgreens Announces Winners for the 2023 Expressions by Walgreens Art Challenge
DEERFIELD, Ill., May 25, 2023--Walgreens is pleased to announce the winners and finalists for our 13th annual Expressions by Walgreens art challenge. The national contest provides monetary awards to winning high school student submissions from around the country.
ReutersWalgreens fights 'staggering' $642 million arbitration award to Humana
National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice." Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana. Separately, Humana asked the U.S. court to confirm the award.
- Reuters
Walgreens fights 'staggering' $642 mln arbitration award to Humana
National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice." Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana.
Motley FoolIs Walgreens Boots Alliance Stock a Buy Now?
Household name and dividend growth stock Walgreens Boots Alliance (NASDAQ: WBA) hasn't been good to shareholders for some time now. Walgreens is transitioning its business beyond prescriptions and retail stores and is working through a bloated balance sheet from an acquisition spree over the past few years. Here is where Walgreens stands and whether you should consider buying shares or wait it out.
Motley FoolIs It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
The Dow Jones Industrial Average was the best-performing of the three major indexes in 2022, but 2023 hasn't been as kind to the blue chip index. The regional banking crisis has hit the Dow hard, and the rebound in tech stocks has also left it lagging behind the S&P 500 and Nasdaq Composite, which have more exposure to the tech sector. As you can see from the chart below, the Dow is actually down slightly for the year even as the other two indexes have delivered solid gains.
Motley FoolCan Walgreens Succeed in This Market Where CVS Failed?
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
Motley FoolCould Walgreens Boots Alliance Stock Help You Become a Millionaire?
The stock doesn't have a great track record, but could that change as it pivots toward healthcare?
